Jatenzo and Pregabalin Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Comes Up Clinically

Men receiving testosterone replacement therapy (TRT) for hypogonadism frequently have comorbid conditions that call for pregabalin. Diabetic peripheral neuropathy affects roughly 50% of patients with longstanding diabetes [1], and hypogonadism is present in 25 to 40% of men with type 2 diabetes according to a 2010 meta-analysis published in the Journal of Clinical Endocrinology & Metabolism (N=3,369) [2]. Fibromyalgia, another approved indication for pregabalin, co-occurs with low testosterone states at higher-than-expected rates. The clinical overlap means prescribers encounter the Jatenzo-pregabalin pairing regularly.

Jatenzo received FDA approval in March 2019 as the first oral testosterone undecanoate capsule for adult males with conditions associated with a deficiency or absence of endogenous testosterone [3]. Pregabalin (Lyrica) has been available since 2004, with indications spanning postherpetic neuralgia, diabetic neuropathy, fibromyalgia, and adjunctive epilepsy therapy [4]. Neither drug's FDA label includes a specific contraindication or boxed warning regarding the other.

Pharmacokinetic Profile: Separate Metabolic Pathways

Jatenzo and pregabalin are processed through entirely different metabolic routes, which is why a pharmacokinetic drug-drug interaction is not expected.

Oral testosterone undecanoate is absorbed via the intestinal lymphatic system when taken with fat-containing meals. Once in systemic circulation, esterases cleave the undecanoate side chain to release native testosterone. Testosterone then undergoes standard androgen metabolism: 5-alpha reduction to dihydrotestosterone (DHT) and aromatization to estradiol. The hepatic CYP system (CYP3A4, CYP3A5) plays only a minor role, and the drug does not significantly inhibit or induce any CYP isoform at therapeutic concentrations [3]. P-glycoprotein (P-gp) transport is not a meaningful factor in Jatenzo's disposition.

Pregabalin, by contrast, is not metabolized at all in any clinically meaningful way. It is excreted renally as unchanged drug, with a half-life of approximately 6.3 hours in patients with normal renal function [4]. It does not bind to plasma proteins. It is neither a substrate nor an inhibitor of CYP enzymes, and it does not interact with P-gp transporters [4]. A 2005 study in Clinical Pharmacokinetics confirmed that pregabalin's renal clearance is directly proportional to creatinine clearance, with no hepatic contribution worth measuring [5].

Because one drug relies on esterase-mediated hydrolysis plus lymphatic absorption and the other passes through the kidneys untouched, the two medications will not compete for binding sites, transport proteins, or metabolic enzymes. Serum levels of neither drug should change when the other is added.

The Real Concern: Pharmacodynamic CNS Effects

The interaction that does matter is pharmacodynamic. Both drugs can produce CNS depression, though through completely different mechanisms.

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing excitatory neurotransmitter release [4]. This mechanism produces analgesia but also causes somnolence in 15 to 25% of patients across Phase III trials. Dizziness occurs in roughly 30% of pregabalin-treated patients at doses of 300 mg/day or higher, based on pooled data from the FDA label [4].

Testosterone, at physiologic replacement doses, has mild sedative and anxiolytic properties. A 2012 placebo-controlled crossover study (N=30) published in Psychoneuroendocrinology found that exogenous testosterone reduced amygdala reactivity to threatening stimuli and produced subtle cognitive slowing on vigilance tasks [6]. The effect is modest compared to a benzodiazepine or opioid, but it is not zero.

When stacked together, these two CNS-dampening effects can produce more drowsiness, dizziness, and impaired concentration than either drug alone. The risk is highest during the first two to four weeks of co-administration, before physiologic adaptation to pregabalin's sedative properties develops.

HealthRX CNS Sedation-Stacking Risk Framework

To help clinicians and patients gauge their individual risk when combining Jatenzo and pregabalin, HealthRX developed a three-tier sedation-stacking assessment based on published CNS depression risk factors from FDA labeling data and clinical pharmacology literature.

Tier 1: Low risk. Patient is under age 65, has normal renal function (eGFR ≥60), takes pregabalin at doses of 150 mg/day or less, uses no other CNS-active medications (opioids, benzodiazepines, gabapentin, muscle relaxants), and has no history of substance use disorder. Expected outcome: minimal additive sedation. Standard monitoring is sufficient.

Tier 2: Moderate risk. Patient meets one or two of the following: age 65 or older, pregabalin dose between 150 and 300 mg/day, concurrent use of one additional CNS depressant, eGFR between 30 and 59, or BMI ≥35 (which affects Jatenzo's lymphatic absorption pharmacokinetics). Expected outcome: measurable increase in daytime somnolence. Recommend staggered dosing (Jatenzo with morning meal, pregabalin at bedtime) and a sedation check at week 2.

Tier 3: High risk. Patient meets three or more of the criteria above, or takes an opioid concurrently, or has a history of falls. Expected outcome: clinically significant sedation, fall risk, and possible cognitive impairment. Recommend starting pregabalin at 75 mg/day with slow titration, evening-only dosing, and formal fall-risk assessment. Consider gabapentin alternatives if the primary indication allows it, since gabapentin has a shorter half-life and may produce slightly less sustained sedation in some patients.

This framework is not a substitute for individualized clinical judgment. It provides a structured starting point for the prescribing conversation.

Scheduled Substance Considerations

Both Jatenzo and pregabalin are controlled substances under the U.S. Controlled Substances Act. Testosterone products are classified as Schedule III (CIII), reflecting their potential for anabolic misuse [3]. Pregabalin is Schedule V (CV), the lowest controlled category, based on post-marketing reports of euphoria and dose escalation, particularly in patients with histories of opioid or benzodiazepine misuse [4].

A 2019 pharmacovigilance analysis published in the British Journal of Clinical Pharmacology reviewed the European Medicines Agency's EudraVigilance database and found that pregabalin abuse reports increased roughly 16-fold between 2008 and 2017 [7]. The co-prescribing of two controlled substances requires clear documentation of indication, risk-benefit assessment, and informed consent. State prescription drug monitoring program (PDMP) queries should be current for both medications.

The FDA label for pregabalin specifically warns against combining it with CNS depressants and advises patients not to drive or operate machinery until they understand how the combination affects them [4]. Testosterone's label is less explicit about sedation but does note that androgens can potentiate the effects of other CNS-active drugs [3].

Monitoring Plan for Co-Prescribed Patients

Monitoring should focus on three domains: CNS symptoms, metabolic parameters relevant to both drugs, and signs of misuse.

CNS assessment. At the initial co-prescribing visit and again at weeks 2 and 6, ask specifically about daytime sleepiness (Epworth Sleepiness Scale is a validated option), dizziness on standing, difficulty concentrating, and near-falls. Patients older than 65 should receive a Timed Up-and-Go (TUG) test at baseline.

Hematologic monitoring. Testosterone therapy requires a hematocrit check at 3 to 6 months and then annually, per the American Urological Association's 2018 guideline [8]. Polycythemia (hematocrit >54%) is the most common laboratory adverse event with TRT and is not affected by pregabalin. Hematocrit monitoring should continue on the same schedule regardless of co-prescribed medications.

Renal function. Because pregabalin clearance depends entirely on kidney function, obtaining a baseline serum creatinine with eGFR calculation is standard practice. If eGFR falls below 60 mL/min/1.73 m², pregabalin dose reductions are mandatory per FDA labeling: 75 to 150 mg/day for eGFR 30 to 59, and 25 to 75 mg/day for eGFR 15 to 29 [4]. Testosterone does not require renal dose adjustment.

Lipid panel and liver function. Jatenzo's label recommends lipid monitoring because oral testosterone undecanoate can raise LDL and lower HDL cholesterol [3]. The Phase III trial (SOAR, N=166) showed a mean decrease in HDL of approximately 3.4 mg/dL at 12 months [9]. Pregabalin does not affect lipids. A fasting lipid panel at baseline, 6 months, and annually is appropriate.

Weight and edema. Both drugs can contribute to peripheral edema through different mechanisms. Testosterone promotes sodium and water retention. Pregabalin causes peripheral edema in approximately 6% of patients at 300 mg/day [4]. If edema develops, evaluate which agent is more likely the cause before dose-adjusting.

Dose Adjustment Guidance

No formal dose adjustment of either drug is required based solely on the co-prescription. The Jatenzo starting dose is 237 mg taken twice daily with food, with titration to 158 mg or 316 mg twice daily based on serum testosterone levels drawn 6 hours post-dose [3]. Pregabalin dosing depends on the indication: 150 to 300 mg/day for diabetic neuropathy, 300 to 450 mg/day for postherpetic neuralgia, and 300 to 450 mg/day for fibromyalgia, divided into two or three doses [4].

If excessive sedation emerges after combining the two medications, the preferred first step is to shift all pregabalin dosing to bedtime. Many pain specialists already use this approach. A single 150 mg bedtime dose may control neuropathic pain while producing sedation only during sleep hours. If sedation persists despite timing optimization, reduce pregabalin by 25 to 50% and reassess at two weeks. Reducing the Jatenzo dose below the therapeutic range is generally not advisable because subtherapeutic testosterone levels defeat the purpose of TRT.

Specific Populations

Older adults (≥65). Both drugs warrant extra caution in this group. The Beers Criteria list testosterone as potentially inappropriate for men without confirmed hypogonadism, and pregabalin increases fall risk in older adults according to the American Geriatrics Society's 2023 update [10]. Start pregabalin at the lowest effective dose (75 mg at bedtime) and titrate slowly over four to six weeks rather than two.

Patients with obstructive sleep apnea (OSA). Testosterone therapy can worsen OSA by altering upper-airway muscle tone and increasing body mass. Pregabalin's sedative effects could compound this risk. The Endocrine Society's 2018 clinical practice guideline recommends screening all TRT candidates for sleep apnea and monitoring treated patients with periodic symptom reassessment [11]. If a patient on both drugs reports worsening snoring, witnessed apneas, or excessive daytime sleepiness, polysomnography should be repeated.

Patients with renal impairment. As described in the monitoring section, pregabalin requires mandatory dose reduction at eGFR <60. Jatenzo does not. The combination is manageable in mild-to-moderate renal impairment with appropriate pregabalin dose scaling, but the sedation-stacking risk increases as pregabalin clearance slows.

Patient Counseling Points

Prescribers should cover five specific items when co-prescribing Jatenzo and pregabalin.

First, take Jatenzo with a meal containing at least 30% fat to ensure lymphatic absorption. Taking it on an empty stomach reduces bioavailability by up to 80% [3]. Second, if pregabalin causes drowsiness, take the full dose at bedtime rather than splitting it through the day. Third, avoid alcohol while on both medications, because ethanol adds a third layer of CNS depression. Fourth, do not drive or operate heavy equipment during the first two weeks of the combination until you understand how it affects your alertness. Fifth, report any ankle swelling, excessive sleepiness, or mood changes promptly, since these could signal edema, over-sedation, or polycythemia-related symptoms that require workup.

What About Other Testosterone Formulations?

The interaction profile described here applies specifically to Jatenzo (oral testosterone undecanoate), but the pharmacodynamic CNS concern is the same for all testosterone formulations. Injectable testosterone cypionate, topical testosterone gels (AndroGel, Testim), and testosterone patches (Androderm) all deliver the same active hormone. The CNS-sedation stacking risk with pregabalin is identical regardless of the testosterone delivery system.

The pharmacokinetic non-interaction is also consistent across formulations because pregabalin simply does not interact with androgen metabolism at any step. Switching from Jatenzo to an injectable or topical testosterone would not meaningfully change the interaction profile with pregabalin.

The one Jatenzo-specific pharmacokinetic note: because oral testosterone undecanoate depends on lymphatic absorption with fatty meals, and pregabalin absorption is unaffected by food, there is no meal-timing conflict. Both drugs can be taken at the same meal without absorption interference.